All News

Chris O’Dell, SVP of market solutions at Turquoise Health, details the ways that the President’s new program differs from previous programs.

Researchers reveal that GLP-1 medication Ozempic may reduce biological age, offering new hope in the fight against aging and related health issues.

Lynkuet, a hormone-free therapeutic option for hot flashes associated with menopause, is expected to be available in the United States in November 2025.

In today’s Pharmaceutical Executive Daily, we cover the emergence of TrumpRx and its implications for direct-to-consumer drug commercialization, new funding momentum across rare disease R&D, and Eli Lilly’s definitive agreement to acquire Aderum Biotechnologies.

GSK's Blenrep gains FDA approval, offering new hope for multiple myeloma patients with improved survival rates and community access.

Eli Lilly plans to acquire Adverum Biotechnologies for $3.56 per share, enhancing its portfolio in innovative genetic medicines for vision restoration.

AI transforms pharmaceutical operations by automating workflows, ensuring transparency, and enhancing compliance, driving efficiency and innovation in healthcare.

The model imagines a new future in which traditional pharmacy distribution and access channels are bypassed.

Chris O’Dell, SVP of market solutions at Turquoise Health, discusses why it's important to a shine a light on this aspect of the healthcare ecosystem.

Pharma investments surge as companies like Summit Therapeutics and Elevara Medicines secure funding to advance innovative drug development and clinical trials.

The acquisition brings together two leaders in mRNA innovation, strengthening BioNTech’s oncology strategy and expanding its R&D and commercialization capabilities.

The decision impacts hopes for preventing congenital infections, although the company is continuing other research initiatives.

The acquisition aims to enhance Alkermes' entry into the sleep medicine market and expanding its product portfolio.

Chris O’Dell, SVP of market solutions at Turquoise Health, explains the timeline to expect changes to prescription drug prices based on current DTC trend.

In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to reject a petition calling for Tylenol label changes, and industry insights from Bob Mauch on building a stronger, more resilient pharmaceutical supply chain.

Novo Nordisk faces significant board changes and stock declines as it navigates governance conflicts with its foundation, aiming for future growth.

In this video discussion with Pharmaceutical Executive, Michael J. Hennessy Jr., chairman and CEO of MJH Life Sciences, and Jason Brown, CEO of BPD Healthcare, discuss how the deal came together and what it means for healthcare executives navigating an increasingly complex marketplace.

Recent research shows mRNA COVID vaccines significantly enhance survival rates in cancer patients undergoing immunotherapy, potentially revolutionizing cancer treatment.

Explore CEO insights on decision-making in manufacturing, focusing on risk management, packaging challenges, and strategies for product safety and quality.

Clinical trial sites face persistent payment delays and complex processes, risking their viability and impacting drug development. Solutions prioritize transparency and flexibility.

At HLTH 2025, the entrepreneur announced a collaboration between Cost Plus Drugs and President Trump’s TrumpRx platform aimed at improving transparency, reducing drug costs, and reshaping how Americans access their prescriptions.

The collaboration will focus on enhancing cancer therapies through next-gen immuno-oncology and ADC treatments for solid tumors.

“This is about building a powerful bridge between the science that transforms lives and the systems that deliver that transformation,” said Michael J. Hennessy Jr., MJH Life Sciences chairman and CEO, of the BPD Healthcare acquisition.

Jesse Mendelsohn, executive vice president at Model N, discusses the broader issues impacting drug prices.

Peptilogics Founder and CEO, Jonathan Steckbeck, explained that PLG0206’s membrane-active mechanism enables it to destroy both active and dormant biofilm bacteria overcoming a key limitation of traditional antibiotics.

Many of the biodiversity risks associated with pharmaceutical production occur beyond the direct operational control of pharmaceutical businesses, whic means that addressing them requires a collaborative, systemic approach to sustainability.

Cencora CEO Bob Mauch discusses the lessons learned during his first year at the helm—and tackling a complex future for pharma distribution.

The proposed change would add a warning about an increased risk of autism, despite a lack of scientific evidence connecting the medication to the condition.